Equity in HTA: what doesn’t get measured, gets marginalised

When making recommendations about the public funding of new health technologies, policy makers typically pay close attention to quantitative evidence about the comparative effectiveness, cost effectiveness and budget impact of those technologies – what we might call “efficiency” criteria. Less atten...

Descripción completa

Detalles Bibliográficos
Autores principales: Cookson, Richard, Mirelman, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502411/
https://www.ncbi.nlm.nih.gov/pubmed/28694961
http://dx.doi.org/10.1186/s13584-017-0162-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502411/
https://www.ncbi.nlm.nih.gov/pubmed/28694961
http://dx.doi.org/10.1186/s13584-017-0162-3

Ejemplares similares